(World J Surg Oncol[TA])
5,972 results
  • Primary pulmonary osteosarcoma: a case report, literature review and pooled analysis. [Case Reports]
    World J Surg Oncol. 2026 Jul 22; 24(1).Zhou J, Chen X, … Zuo PWJ
  • CONCLUSIONS: PPOS is an aggressive malignancy with poor prognosis. Age and surgical resection were found to be crucial prognostic factors. A combination of surgery and chemotherapy may offer additional survival benefits to selected patients. Given that the benefits of surgery were observed across all age groups and that no difference in survival was observed according to tumor size among surgically treated patients, advanced age and larger tumor size alone should not preclude consideration of surgical intervention in patients with adequate performance status. Larger multi-institutional studies are needed to validate these findings.
  • Not all prolific letter writers are alike. [Letter]
    World J Surg Oncol. 2026 Oct 15; 24(1).Matsubara SWJ
  • Concerns have recently been raised that AI-assisted "letter-bombing" may distort medical publishing. Although I share these concerns, prolific Letter writing can arise for legitimate reasons. Using my own publication history as an example, I illustrate how retirement, loss of access to primary data, and broader academic interests naturally shifted my publications from original articles toward Let…
  • Serous cystadenocarcinoma of the pancreas: a population-based study. [Journal Article]
    World J Surg Oncol. 2026 Sep 28; 24(1).Dotevall T, Kolmodin E, … Ansari DWJ
  • CONCLUSIONS: Pancreatic SCAc is a rare malignancy with frequent involvement of the pancreatic body or tail. Surgical resection was the most common treatment, whereas chemotherapy was used in a minority of patients. Population-based data suggest relatively favorable long-term survival.
  • Prognostic utility of the Charlson comorbidity index in pancreatic cancer: a systematic review and meta‑analysis. [Systematic Review]
    World J Surg Oncol. 2026 Aug 07; 24(1).Yang J, Wang S, … Song HWJ
  • CONCLUSIONS: The current meta-analysis provides quantitative evidence from observational studies to support the CCI and CACI as factors associated with survival in patients with pancreatic cancer. However, given the substantial heterogeneity and observational design of the included studies, these indices should be interpreted as prognostic association markers rather than standalone clinical decision tools. The findings should be cautiously interpreted. Future prospective studies are required for validation. Integrated prediction models combining these indices with molecular markers should be explored.